Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma

Table 2 General characteristics of all patients with stage IV duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma, n (%)

	Total, n = 31	Local treatment of metastases, n = 7	Systemic treatment, n = 20	Supportive care, n = 4
Age
Age, median [IQR]	63 [58-71]	69 [59-73]	62 [52-73]	63 [58-67]
Sex
Male	17	5	11	1
Origin
Duodenum	27	7	17	3
Papilla (intestinal-type)	4	0	3	1
ASA
ASA I	3	1	2	0
ASA II	13	4	8	1
ASA III	4	1	1	2
NR	11	1	9	1
Metastatic site
Liver	13	5	7	1
Lymphatic	4	2	2	0
Lung	2	0	2	0
Peritoneal	9	0	6	3
Lung + liver or lymphatic	3	0	3	0
Number of liver oligometastases1 (%)
Number, median [IQR]	2 [1-7]	2 [1-3]	4 [1-15]	3
Local treatment of liver metastases
Metastasectomy	5 (14.7)	5	N/A	N/A
Ablation	1 (2.9)	1	N/A	N/A
Metastasectomy + ablation	1 (2.9)	1	N/A	N/A
Systemic therapy
5-FU-LV	1 (2.9)	0	1	0
Capecitabine	5 (14.7)	0	5	0
CAPOX	13 (41.9)	2	11	0
EOX	1 (2.9)	0	1	0
FOLFOX	1 (2.9)	1	0	0
FOLFOX + radiotherapy	1 (2.9)	0	1	0
No chemotherapy	6 (19.4)	3	0	3
Unspecified chemotherapy	1 (2.9)	0	1	0
NR	2 (6.5)	1	0	1

¹Only patients with oligometastases of the liver. 5-FU-LV: 5-fluorouracil and leucovorin; CAPOX: Capecitabine and oxaliplatin; EOX: Epirubicine, oxaliplatin and capecitabine; FOLFOX: 5-fluorouracil and oxaliplatin; IQR: Interquartile range; NR: Not reported; N/A: Not applicable.